Biotech News

Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow

Charles River (CRL)Charles River2026-06-25 13:46 ESTFDA / regulatory

WILMINGTON, Mass. --(BUSINESS WIRE)--May 11, 2026-- Charles River Laboratories International, Inc. (NYSE: CRL) today announced continued momentum in its digital pathology platform, delivering an end-to-end, AI-enabled workflow that significantly accelerates study timelines, and enhances pathologist

Open original release

Related news

Charles River

Charles River is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

Stock data

Close
Market cap
Exchange
NYSE
Sector
Biotechnology
Location
United States